Predicting resistance to synthetic lethal therapies in cancer

Metin Yazar; Colm J. Ryan

doi:10.64898/2026.10.12.757986

Predicting resistance to synthetic lethal therapies in cancer | ResearchHub

Abstract Background Synthetic lethality (SL) occurs when an alteration in one gene renders cells vulnerable to inhibition of another, offering a strategy for targeted cancer therapy. PARP inhibitors represent the first clinically approved synthetic lethal therapy, and numerous additional candidates are now in clinical trials. Unfortunately, resistance to these therapies is common and impairs their overall effectiveness. Although there is a growing understanding of the factors that predict synthetic lethal interactions, the prediction of mechanisms driving resistance to these effects remains largely unstudied. Here, we sought to determine whether SL resistance could be predicted a priori using protein-protein interaction networks integrated with additional molecular profiles. Methods We curated genome-wide CRISPR-Cas9 chemogenetic resistance screens spanning ten unique SL biomarker-target pairs. For each pair, we extracted resistance genes and computed features capturing protein-protein interactions, gene expression, and essentiality. We compared these features between resistance and non-resistance genes and developed a random forest classifier to predict resistance. Model performance was assessed using random-split and structured leave-one-out schemes based on biomarkers, targets, and SL pairs to ensure robust generalisation. Independent validation of the model was performed by assessing its ability to predict resistance to two SL therapies currently in clinical trials, MTAP-PRMT5 and ATM-ATR. Results Resistance genes were significantly enriched among the protein-protein interaction partners of SL pairs across multiple datasets, suggesting functional interaction networks can aid the prioritisation of resistance mechanisms. Resistance genes tended to be more co-expressed with their associated target and also displayed distinct essentiality patterns. Although no individual feature was strongly predictive, integrating all features in a random forest model improved discrimination between resistance and non-resistance genes. Under leave-one-SL-pair-out cross-validation — our most stringent test of generalisation — the model achieved a mean area under the receiver operating characteristic curve (AUROC) of 0.72 across ten pairs (range 0.57-0.91; mean average precision ∼9%); a random train-test split gave a higher AUROC (∼0.78) that we treat as an optimistic upper bound, since biomarkers and targets are shared across folds. Average precision remained low in absolute terms, reflecting the inherent challenge of predicting extremely rare resistance events ( Conclusions Resistance to synthetic lethal therapies arises, at least in part, from predictable patterns of network connectivity, transcriptional coordination, and context-dependent essentiality. Our integrative framework provides a computational approach for anticipating resistance mechanisms across the expanding landscape of synthetic lethal therapies, offering a foundation for designing more durable and effective combination treatments.

External reference records

Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: A single-arm, phase II trial

10.1200/jco-24-01266 · 2025

10.1038/s41586-019-1103-9

Predicting synthetic lethal interactions using conserved patterns in protein interaction networks

10.1371/journal.pcbi.1006888 · 2019

10.1023/a:1010933404324

Generating simple random graphs with prescribed degree distribution

10.1007/s10955-006-9168-x · 2006

10.1038/nature03443

10.1016/j.cell.2010.03.012

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours

10.1038/s41416-023-02436-2 · 2024

Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens

10.1038/s41467-020-19961-w · 2020

A global genetic interaction network maps a wiring diagram of cellular function

10.1126/science.aaf1420 · 2016

Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines

10.1016/j.cels.2021.08.006 · 2021

10.25452/figshare.plus.24667905.v2

10.1038/s41556-018-0140-1

MAGICAL: A multi-class classifier to predict synthetic lethal and viable interactions using protein-protein interaction network

10.1371/journal.pcbi.1012336 · 2024

10.1038/s41388-022-02482-9

10.1093/nar/gkaa882

10.1093/nar/gkae1071

10.1158/2159-8290.cd-23-0669

10.1038/nature03445

10.1038/s41586-022-04638-9

10.1038/s41573-025-01273-7

10.1126/science.aaz1776

10.1016/j.cell.2018.03.050

10.25080/tcwv9851

10.1158/1535-7163.mct-14-0406

10.1038/s41586-020-2649-2

10.1158/0008-5472.can-18-2711

10.1038/nrc3599

10.1038/s41573-019-0046-z

10.1109/mcse.2007.55

10.1016/j.cell.2016.06.017

10.1158/2159-8290.cd-12-0049

10.1038/nbt1096

10.1158/0008-5472.can-25-1464

10.7554/elife.18970

MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (New York

10.1126/science.aad5214 · 2016

10.1126/science.aao1729

PARP inhibitor resistance: the underlying mechanisms and clinical implications

10.1186/s12943-020-01227-0 · 2020

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

10.1158/0008-5472.can-21-4339 · 2022

10.1093/nar/gkab628

Additional external references

Genome-wide CRISPR/Cas9 screening for drug resistance in tumors

10.3389/fphar.2023.1284610 · doi-reference

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

10.1038/s41467-021-23463-8 · doi-reference

PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours

10.1038/s41401-021-00841-y · doi-reference

10.1098/rsob.220118

10.1098/rsob.220118 · doi-reference

10.1073/pnas.0802655105

10.1073/pnas.0802655105 · doi-reference

ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition

10.1016/j.celrep.2017.01.031 · doi-reference

10.1158/2159-8290.cd-13-0631

10.1158/2159-8290.cd-13-0631 · doi-reference

10.1038/s41592-019-0686-2

10.1038/s41592-019-0686-2 · doi-reference

10.1158/2159-8290.cd-13-0617

10.1158/2159-8290.cd-13-0617 · doi-reference

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

10.1038/nsmb.2076 · doi-reference

10.1093/nar/gkac1000

10.1093/nar/gkac1000 · doi-reference

Predicting resistance to synthetic lethal therapies in cancer

Referenced works

Cited by

External reference records

Additional external references